Compare RYAM & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAM | ORIC |
|---|---|---|
| Founded | 1926 | 2014 |
| Country | United States | United States |
| Employees | 2325 | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.8M | 837.3M |
| IPO Year | 2014 | 2020 |
| Metric | RYAM | ORIC |
|---|---|---|
| Price | $9.86 | $10.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $14.00 | ★ $19.73 |
| AVG Volume (30 Days) | 720.2K | ★ 2.4M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,466,397,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.35 | $4.52 |
| 52 Week High | $11.85 | $14.93 |
| Indicator | RYAM | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 46.78 |
| Support Level | $9.01 | $9.75 |
| Resistance Level | $11.62 | $10.79 |
| Average True Range (ATR) | 0.53 | 0.98 |
| MACD | -0.11 | 0.06 |
| Stochastic Oscillator | 35.37 | 52.24 |
Rayonier Advanced Materials Inc engaged in the production and sale of high-purity cellulose and other cellulose-based materials derived from renewable wood fiber. The company operates through five segments: Cellulose Specialties, which produces purified cellulose used in products such as filters, pharmaceuticals, food additives and electronics; Biomaterials, which produces products including biofuels, lignosulfonates and other bio-based chemicals; Cellulose Commodities, which manufactures absorbent and viscose pulp used in textiles and hygiene products; Paperboard, which produces coated paperboard used for packaging and printing applications; and High-Yield Pulp, which produces pulp used in paperboard, packaging and printing paper products.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.